Exact Sciences Corp
NASDAQ:EXAS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
41.33
75.72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Exact Sciences Corp
Exact Sciences Corp
Current Portion of Long-Term Debt
Exact Sciences Corp
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Current Portion of Long-Term Debt
$249m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
90%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Current Portion of Long-Term Debt
$12.6B
|
CAGR 3-Years
24%
|
CAGR 5-Years
19%
|
CAGR 10-Years
89%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Current Portion of Long-Term Debt
$3.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
12%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Exact Sciences Corp
Glance View
Exact Sciences Corp. has crafted a compelling narrative in the realm of molecular diagnostics, primarily revolutionizing the way cancer is detected and managed. Founded with a mission to eradicate cancer's mortality through early detection, the company has carved out a prominent niche with its flagship product, Cologuard. This non-invasive, stool-based DNA screening test for colorectal cancer offers an alternative to traditional colonoscopy, making cancer screening more accessible and less intimidating. By capitalizing on advancements in genomics and leveraging sophisticated algorithmic analysis, Exact Sciences has managed to transform routine medical testing, garnering robust support from both physicians and patients. The test, approved by regulatory bodies and integrated into various insurance plans, forms the cornerstone of Exact Sciences’ revenue model, contributing significantly to its bottom line by combining upfront test fees with ongoing follow-up services. Beyond colorectal cancer, Exact Sciences is ambitiously expanding its portfolio through both internal research and strategic acquisitions. The company's vision extends to a comprehensive suite of diagnostic tools covering multiple cancer types, notably breast and liver cancer, reflecting its commitment to innovation and growth. Recent acquisitions, such as Thrive Earlier Detection and PreventionGenetics, have fortified its capabilities in early-stage cancer detection and genetic testing, positioning it well for future opportunities. This strategic expansion not only broadens its product base but also enhances recurring revenue streams through continued engagement with healthcare providers and patients. By intertwining cutting-edge science with a savvy commercial strategy, Exact Sciences is shaping the future of personalized medicine while steadily augmenting its financial health.
See Also
What is Exact Sciences Corp's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
249m
USD
Based on the financial report for Sep 30, 2024, Exact Sciences Corp's Current Portion of Long-Term Debt amounts to 249m USD.
What is Exact Sciences Corp's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
90%
Over the last year, the Current Portion of Long-Term Debt growth was 359%. The average annual Current Portion of Long-Term Debt growth rates for Exact Sciences Corp have been -8% over the past three years , -5% over the past five years , and 90% over the past ten years .
You don't have any saved screeners yet
